Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanna Rosenbaum

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Clinics and Research in Hepatology and Gastroenterology|August 28, 2025
Multiorgan fibrosis in Gaucher disease type I: an unmet goal of enzyme replacement therapyZufit Hexner-Erlichman, Nimer Assy, Nayaf Habashi, et al.
American Journal of Clinical Pathology|August 30, 2006
Traumatic ulcerative granuloma with stromal eosinophilia: a reactive lesion of the oral mucosaAbraham Hirshberg, Ninette Amariglio, Sharon Akrish, et al.
American Journal of Medical Genetics. Part A|January 11, 2003
Gaucher disease associated with parkinsonism: four further case reportsJudit Várkonyi, Hanna Rosenbaum, Nicole Baumann, et al.
BMJ Open|January 24, 2019
Population-based cohort of 500 patients with Gaucher disease in IsraelDena H Jaffe, Natalie Flaks-Manov, Arriel Benis, et al.
American Journal of Hematology|April 23, 2016
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Suma P Shankar, Milan Petakov, et al.
British Journal of Haematology|July 28, 2007
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher diseaseDerralynn Hughes, Maria Domenica Cappellini, Marc Berger, et al.
American Journal of Hematology|September 29, 2018
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialElena Lukina, Nora Watman, Marta Dragosky, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Blood Cells, Molecules & Diseases|May 20, 2014
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatmentElena Lukina, Nora Watman, Marta Dragosky, et al.
Journal of Clinical Medicine|September 28, 2023
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort StudyShoshana Revel-Vilk, Royston Mansfield, Neta Feder-Krengel, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Clinics and Research in Hepatology and Gastroenterology|August 28, 2025
Multiorgan fibrosis in Gaucher disease type I: an unmet goal of enzyme replacement therapyZufit Hexner-Erlichman, Nimer Assy, Nayaf Habashi, et al.
American Journal of Clinical Pathology|August 30, 2006
Traumatic ulcerative granuloma with stromal eosinophilia: a reactive lesion of the oral mucosaAbraham Hirshberg, Ninette Amariglio, Sharon Akrish, et al.
American Journal of Medical Genetics. Part A|January 11, 2003
Gaucher disease associated with parkinsonism: four further case reportsJudit Várkonyi, Hanna Rosenbaum, Nicole Baumann, et al.
BMJ Open|January 24, 2019
Population-based cohort of 500 patients with Gaucher disease in IsraelDena H Jaffe, Natalie Flaks-Manov, Arriel Benis, et al.
American Journal of Hematology|April 23, 2016
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Suma P Shankar, Milan Petakov, et al.
British Journal of Haematology|July 28, 2007
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher diseaseDerralynn Hughes, Maria Domenica Cappellini, Marc Berger, et al.
American Journal of Hematology|September 29, 2018
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialElena Lukina, Nora Watman, Marta Dragosky, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Blood Cells, Molecules & Diseases|May 20, 2014
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatmentElena Lukina, Nora Watman, Marta Dragosky, et al.
Journal of Clinical Medicine|September 28, 2023
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort StudyShoshana Revel-Vilk, Royston Mansfield, Neta Feder-Krengel, et al.
Pageof 3